MedTrace Logo

Liver Disease in Patients With alpha1-antitrypsin Deficiency

NCT02929940 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2017-05-31

No results posted yet for this study

Summary

Alpha1-antitrypsin deficiency (AATD) is the third most common genetic disorder leading to death worldwide. Apart from lung disease, AATD also leads to liver involvement in up to 50% of patients. Hence, liver involvement is the second most common cause of morbidity and mortality in AATD patients. But the natural history of disease in adults is not well understood and specific therapies are still in the phase of preclinical studies. Despite these facts and the therapeutic and preventative potential, the AATD-related liver disease is still largely being neglected by both the patients and the healthcare professionals.

To improve the hepatologic care of patients with AATD, the investigators initiated a prospective multi-center study in Europe that systematically evaluates the liver function in these patients and their relatives. The investigators cooperate with both patient organizations as well as with lung centers specialized on AATD-related lung disease.

Conditions

  • alpha1-antitrypsin Deficiency

Interventions

OTHER

No intervention

No Intervention, observational

Sponsors & Collaborators

  • RWTH Aachen University

    lead OTHER

Principal Investigators

  • Pavel Strnad, MD · RWTH Aachen University

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2020-04-30
Completion
2020-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02929940 on ClinicalTrials.gov